Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

3.

The influence of HLA-matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMA. European Organization for Research and Treatment of Cancer. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

Keating S, de Witte T, Suciu S, Willemze R, Hayat M, Labar B, Resegotti L, Ferrini PR, Caronia F, Dardenne M, Solbu G, Petti MC, Vegna ML, Mandelli F, Zittoun RA.

Br J Haematol. 1998 Sep;102(5):1344-53.

PMID:
9753069
4.

Prognostic factors of patients with acute myeloid leukemia (AML) allografted in first complete remission: an analysis of the EORTC-GIMEMA AML 8A trial. The European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto (GIMEMA) Leukemia Cooperative Groups.

Keating S, Suciu S, de Witte T, Mandelli F, Willemze R, Resegotti L, Broccia G, Thaler J, Labar B, Damasio E, Bizzi B, Rotoli B, Vekhoff A, Muus P, Petti MC, Dardenne M, Solbu G, Vegna ML, Zittoun RA.

Bone Marrow Transplant. 1996 Jun;17(6):993-1001.

PMID:
8807105
6.

High-dose cytarabine in acute leukemia: toxicity and pharmacokinetics.

Pommier Y, Pochat L, Marie JP, Zittoun RA.

Cancer Treat Rep. 1983 Apr;67(4):371-3.

PMID:
6850654

Supplemental Content

Loading ...
Support Center